Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose (SAD and MAD) Study
by thaan@22fillmore | Jun 9, 2023